NCT05027958View on ClinicalTrials.gov

Characterization of Tissue-Specific Immune Responses to Bronchoscopic Instillation of Mycobacterial Antigens Into the Human Lung

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

May 3, 2022

Primary Completion Date

November 7, 2024

Study Completion Date

December 8, 2024

Conditions
HealthyLatent Tuberculosis Infection (LTBI)
Interventions
DRUG

Tuberculin Purified Protein Derivative

PPD administered through the airways to elicit the development of alveolar inflammation challenge dose of 0.5 TU

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH